Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-22-028180
Filing Date
2022-11-03
Accepted
2022-11-03 16:08:35
Documents
79
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ardx-20220930.htm   iXBRL 10-Q 1898519
2 EX-31.1 ardx-20220930xex311.htm EX-31.1 9860
3 EX-31.2 ardx-20220930xex312.htm EX-31.2 9865
4 EX-32.1 ardx-20220930xex321.htm EX-32.1 6534
10 ardx-20220930_g1.jpg GRAPHIC 75659
  Complete submission text file 0001628280-22-028180.txt   8148614

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ardx-20220930.xsd EX-101.SCH 58101
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ardx-20220930_cal.xml EX-101.CAL 65342
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ardx-20220930_def.xml EX-101.DEF 268600
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ardx-20220930_lab.xml EX-101.LAB 679533
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ardx-20220930_pre.xml EX-101.PRE 437633
73 EXTRACTED XBRL INSTANCE DOCUMENT ardx-20220930_htm.xml XML 1276816
Mailing Address 34175 ARDENWOOD BLVD. FREMONT CA 94555
Business Address 34175 ARDENWOOD BLVD. FREMONT CA 94555 510-745-7047
ARDELYX, INC. (Filer) CIK: 0001437402 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36485 | Film No.: 221358017
SIC: 2834 Pharmaceutical Preparations